SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

GESSI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.715
AS - Asia 12.036
EU - Europa 9.251
SA - Sud America 1.968
AF - Africa 180
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 47.174
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.276
SG - Singapore 4.658
CN - Cina 3.702
IT - Italia 2.654
DE - Germania 1.813
BR - Brasile 1.661
UA - Ucraina 1.465
HK - Hong Kong 1.170
TR - Turchia 1.065
GB - Regno Unito 773
VN - Vietnam 732
FI - Finlandia 536
SE - Svezia 499
RU - Federazione Russa 455
PL - Polonia 285
FR - Francia 274
CA - Canada 209
MX - Messico 189
NL - Olanda 154
IN - India 134
AR - Argentina 127
ID - Indonesia 114
BD - Bangladesh 101
JP - Giappone 88
ZA - Sudafrica 86
ES - Italia 82
BE - Belgio 58
IQ - Iraq 58
LT - Lituania 56
EC - Ecuador 52
AT - Austria 32
CZ - Repubblica Ceca 32
CO - Colombia 28
CL - Cile 26
AE - Emirati Arabi Uniti 25
MA - Marocco 25
UZ - Uzbekistan 24
VE - Venezuela 24
PK - Pakistan 21
PY - Paraguay 20
SA - Arabia Saudita 16
IR - Iran 15
KE - Kenya 15
TN - Tunisia 14
DZ - Algeria 13
IL - Israele 13
NP - Nepal 13
JO - Giordania 12
UY - Uruguay 11
AU - Australia 10
KR - Corea 10
BG - Bulgaria 9
PE - Perù 8
RO - Romania 8
AL - Albania 7
EG - Egitto 7
EU - Europa 7
TW - Taiwan 7
BA - Bosnia-Erzegovina 6
BO - Bolivia 6
IE - Irlanda 6
OM - Oman 6
AZ - Azerbaigian 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
JM - Giamaica 5
LV - Lettonia 5
MY - Malesia 5
PA - Panama 5
PS - Palestinian Territory 5
PT - Portogallo 5
GA - Gabon 4
GE - Georgia 4
GY - Guiana 4
HR - Croazia 4
KZ - Kazakistan 4
LB - Libano 4
MK - Macedonia 4
PH - Filippine 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
BY - Bielorussia 3
CR - Costa Rica 3
GT - Guatemala 3
HU - Ungheria 3
KG - Kirghizistan 3
MO - Macao, regione amministrativa speciale della Cina 3
NI - Nicaragua 3
NO - Norvegia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
CG - Congo 2
CI - Costa d'Avorio 2
ET - Etiopia 2
GR - Grecia 2
IM - Isola di Man 2
LU - Lussemburgo 2
Totale 47.137
Salva come PNG Salva come JPEG
Città #
Singapore 2.792
Woodbridge 2.407
Ashburn 2.182
Fairfield 2.035
Jacksonville 1.588
Chandler 1.581
Houston 1.490
Ann Arbor 1.187
Hong Kong 1.165
Beijing 1.164
Santa Clara 1.123
Wilmington 863
Seattle 835
Cambridge 670
Izmir 517
Nanjing 489
Dallas 466
Los Angeles 421
Princeton 361
Milan 353
Ferrara 314
Munich 304
Boardman 297
Ho Chi Minh City 262
New York 241
Warsaw 241
Shanghai 190
San Diego 172
Nanchang 165
São Paulo 154
Shenyang 152
Dearborn 149
Hanoi 141
Turku 126
Tianjin 124
Mexico City 116
London 112
Addison 111
Hefei 108
Bremen 104
Falkenstein 104
Helsinki 100
Changsha 98
Hebei 98
Rome 92
Buffalo 81
Chicago 80
Jakarta 79
Frankfurt am Main 78
Tokyo 77
Brooklyn 75
Montreal 75
Jiaxing 73
Bologna 66
Orem 64
Jinan 63
San Mateo 60
Stockholm 59
Toronto 58
Moscow 56
Norwalk 56
Brussels 55
The Dalles 55
Florence 54
Denver 53
Rio de Janeiro 52
Johannesburg 51
Mountain View 51
Zhengzhou 50
Kunming 49
San Francisco 49
Poplar 48
Boston 47
Atlanta 43
Falls Church 43
Guangzhou 42
Haiphong 42
Phoenix 42
Belo Horizonte 40
Manchester 39
Chennai 38
Düsseldorf 38
Orange 36
Auburn Hills 35
Council Bluffs 35
Redwood City 35
Da Nang 34
Ningbo 33
Verona 32
Mumbai 31
San Jose 30
Amsterdam 29
Ankara 28
Naples 27
Philadelphia 27
Brasília 26
Hải Dương 25
Porto Alegre 25
Bari 24
Dhaka 24
Totale 30.381
Salva come PNG Salva come JPEG
Nome #
Farmacologia cellulare e molecolare, sistemi di trasmissione e autacoidi. Trasmissione purinergica 1.311
PRIN 2007 Coordinatore Nazionale del progetto Dott. Stefania Gessi- Il recettore A3 dell’adenosina: un potenziale bersaglio per la diagnosi, prognosi e terapia del cancro colorettale 576
Pharmacology of Adenosine Receptors: The State of the Art 300
A glance at adenosine receptors: Novel target for antitumor therapy 267
Alterazioni dei recettori alfa(2) adrenergici delle piastrine umane nell'ipertensione essenziale 267
Medicinal Chemistry, Pharmacology, and Clinical Implications of TRPV1 Receptor Antagonists 261
Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 257
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 242
A1 and A3 adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes 231
Positive allosteric modulation of A1 adenosine receptors as a novel and promising therapeutic strategy for anxiety 231
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 223
Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields 221
The A3 adenosine receptor: history and perspectives 219
Adenosine receptors and human melanoma 218
Pulsed Electromagnetic Field Exposure Reduces Hypoxia and Inflammation Damage in Neuron-Like and Microglial Cells 217
A(2B) adenosine receptors stimulate IL-6 production in primary murine microglia through p38 MAPK kinase pathway 215
Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease 213
N-6-[(Hetero)aryl/(cyclo)alkyl-carbamoyi-methoxy-phenyl]-(2chloro)-5 '-N-ethylearboxamido-adenosines: The first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor 206
Effects of two-carbon bridge region methoxylation of benztropine: discovery of novel chiral ligands for the dopamine transporter 206
Adenosine Receptor Antagonists: Translating Medicinal Chemistry and Pharmacology into Clinical Utility 204
Adenosine receptor targeting in health and disease 204
Multiple sclerosis lymphocytes upregulate A(2A) adenosine receptors that are antiinflammatory when stimulated 201
Cannabinoid CB2 receptor attenuates morphine-induced inflammatory responses in activated microglial cells 201
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 200
The activation of μ-opioid receptor potentiates LPS-induced NF-kB promoting an inflammatory phenotype in microglia 200
[H-3]-MRE 2029-F20, a selective antagonist radioligand for the human A(2B) adenosine receptors 199
Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields 198
Adenosine modulates vascular endothelial growth factor expression via hypoxiainducible factor-1 in human glioblastoma cells. 197
Antioxidant and antiinflammatory effects of epilobium parviflorum, melilotus officinalis and cardiospermum halicacabum plant extracts in macrophage and microglial cells 197
Role and function of A2A and A3 adenosine receptors in patients with ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis 196
Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects? 194
Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells 194
From tyrosine to glycine: Synthesis and biological activity of potent antagonists of the purinergic P2X(7) receptor 193
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 189
Adenosine receptors and cancer 188
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study 188
Water-Soluble Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as Human A3 Adenosine Receptor Antagonists 187
van't Hoff Based Thermodynamics 186
A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells 185
[3H]-MRE 2029-F20, a novel selective antagonist radioligand, for the pharmacological and biochemical characterization of A2B receptors. 185
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells 184
Receptor binding thermodynamics as a tool for linking drug efficacy and affinity 184
HIF-1 neuroprotection through erythropoietin increase in hypoxia: a role for A1 adenosine receptors 182
ALTERATION OF ADENOSINE RECEPTORS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 182
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 182
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors 182
Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells 181
The Anti-Tumor Effect of A(3) Adenosine Receptors Is Potentiated by Pulsed Electromagnetic Fields in Cultured Neural Cancer Cells 181
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists 180
Pathological overproduction: the bad side of adenosine 178
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 178
Synthesis and pharmacology of 6-substituted benztropines: Discovery of novel dopamine uptake inhibitors possessing low binding affinity to the dopamine transporter 177
Binding thermodynamics at A1 and A2A adenosine receptors 176
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats 176
Biological effects of novel 2-amino-3-naphthoylthiophenes as allosteric enhancers of the A1 adenosine receptors 176
M3 muscarinic receptors in peripheral lung parenchima of patients with chronic obstructive pulmonary disease. 175
Expression of A3 adenosine receptors in human lymphocytes: up-regulation in T cell activation 174
A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: A pharmacological and biochemical study. 174
Adenosine Receptors as a Biological Pathway for the Anti-Inflammatory and Beneficial Effects of Low Frequency Low Energy Pulsed Electromagnetic Fields 174
Adenosine receptors in health and disease 173
Agonists and antagonists: Molecular mechanisms and therapeutic applications 173
Alteration of adenosine receptore in patients with chronic obstructive pulmonary disease 173
Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. 172
Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. 172
Binding thermodynamic characterization of human P2X1 and P2X3 purinergic receptors 171
Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A3 adenosine receptors. 171
A(2A) adenosine receptors in human peripheral blood cells 171
3H SCH 58261 labelling of functional A2A adenosine receptors in human neutrophil membranes 171
4-(4-Fluorobenzoyl)-1-[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]piperidine and its derivatives: Synthesis and affinity at 5-HT(2A), 5-HT(2B) and 5- HT(2C) serotonin receptors 171
Binding thermodynamics at the human cannabinoid CB1 and CB2 receptors 170
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. 169
Adenosine and lymphocyte regulation 168
[3H]MRE2029F20 a new selective antagonist radioligand for the human A2B adenosine receptors. 167
Thermodynamic analysis in drug-receptor binding: the A3 adenosine receptor 167
Therapeutic potential of adenosine receptor antagonists and agonists 166
Changes in hippocampal and cortical B1 bradykinin receptor biological activity in two experimental models of epilepsy 166
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 165
Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. 165
Biochemical and pharmacological role of A1adenosine receptors and their modulation as novel therapeutic strategy 165
New potent and selective human adenosine A3 receptor antagonists. 165
Thermodynamics of A2B adenosine receptor binding discriminates agonistic from antagonistic behaviour 164
A convenient synthesis by microwave heating and pharmacological evaluation of novel benzoyltriazole and saccharine derivatives as 5-HT(1A) receptor ligands 164
Binding thermodynamics of 5-HT(1A) receptor ligands 163
Adenosine receptors and cancer 163
Farmacologia cellulare e molecolare, sistemi di trasmissione. Trasmissione purinergica. 162
A3 adenosine receptors in human neutrophils and promyelocitic HL60 cells: a pharmacological and biochemical study. 161
Pyrazolotriazolopyrimidine derivatives sensitize melanoma cells to the chemiotherapic drugs: taxol and vindesine. 161
Deficiency of polycystic kidney disease-1 gene (PKD1) expression increases A(3) adenosine receptors in human renal cells: Implications for cAMP-dependent signalling and proliferation of PKD1-mutated cystic cells. 160
Pulsed electromagnetic field and relief of hypoxia-induced neuronal cell death: The signaling pathway 160
THERMODYNAMICS OF A2B ADENOSINE RECEPTOR BINDING DISCRIMINATES AGONISTIC FROM ANTAGONISTIC BEHAVIOUR 159
Hydrogen sulfide modulates the release of nitric oxide and VEGF in human keratinocytes. 159
Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1-f][1,6]naphthyridines as CB2receptor antagonists/inverse agonists 159
The A3 adenosine receptor: An enigmatic player in cell biology 158
Synthesis, radiolabeling, and preliminary biological evaluation of [H-3]-1-[(S)-N,O-bis-(isoquinolinesulfonyl)-N-methyl-tyrosyl]-4-(o-tolyl )-piperazine, a potent antagonist radioligand for the P2X(7) receptor 157
Pharmacological characterization of adenosine receptors in bovine chondrocytes. 157
[3H] CGS 21680 binding to purified adenosine A2A receptors in human platelets 157
[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 157
Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors 156
MODULATION OF THE AKT/RAS/RAF/MEK/ERK PATHWAY BY A3 ADENOSINE RECEPTOR 156
Expression, pharmacological profile and functional coupling of A2B receptors in a recombinant system and in peripheral blood cells by using a novel selective antagonist radioligand, [3H]MRE2029F20. 156
Totale 20.103
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.228
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 10.795
Totale 221.023
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.443 0 0 0 0 0 445 145 471 76 563 511 232
2021/20223.182 68 328 207 157 141 135 118 174 113 266 459 1.016
2022/20233.721 360 289 119 500 617 497 183 308 461 43 202 142
2023/20242.024 181 253 100 48 230 217 101 133 51 96 100 514
2024/20257.724 188 220 612 424 973 666 314 473 1.036 864 1.071 883
2025/202611.718 2.183 823 1.824 2.718 3.007 1.163 0 0 0 0 0 0
Totale 47.591